Dogwood Therapeutics DWTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.67M+9.6% | $2.34M+0.9% | $14.52M+2,613% | $2.57M+665% | $2.44M+609% | ||
| $2.41M+20.8% | $1.47M-71.9% | $1.29M-27.1% | $1.35M+84.4% | $1.99M+105% | ||
| $5.08M+14.6% | $3.81M-49.5% | $15.81M+587% | $3.92M+267% | $4.43M+237% | ||
| -$5.08M-14.6% | -$3.81M+49.5% | -$15.81M-587% | -$3.92M-267% | -$4.43M-237% | ||
| $77.35K+153% | $52.07K+133% | $80.58K+293% | $111.38K+457% | -$147.09K-746% | ||
| $90.95K+101% | $0+100% | $63.07K+208% | $115.91K+480% | -$6.3M-27,793% | ||
| -$4.99M+53.6% | -$3.75M+51.5% | -$15.75M-590% | -$3.81M-263% | -$10.73M-731% | ||
| -$4.99M+54.4% | -$3.78M+51.1% | -$15.74M-590% | -$3.81M-263% | -$10.92M-746% | ||
| -$0.15+98.2% | —— | -$8.20-300% | -$1.99-73.0% | -$8.45-403% | ||
| -$5.08M-14.6% | -$3.81M+49.5% | -$15.81M-587% | -$3.92M-267% | -$4.43M-237% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Dogwood Therapeutics profitable?
- Dogwood Therapeutics is not currently profitable: it reported a net loss of $28.3M over the trailing twelve months.
- What is Dogwood Therapeutics's earnings per share?
- Dogwood Therapeutics's diluted EPS over the trailing twelve months is $-18.79.
- Where does Dogwood Therapeutics's income statement data come from?
- Every line is extracted from Dogwood Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.